Alpha¹ by KaimenConfidential

Kaimen Rigor review

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA

DOI: 10.1038/s41591-025-03556-3
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/261ca55e-e170-4222-a819-fc98c2c15307 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on weight loss percentage, which is a surrogate endpoint for clinical outcomes such as cardiovascular morbidity and mortality. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking weight loss to hard clinical outcomes in this specific context.
“The primary outcome was met; early nonresponders assigned to BT + AOM had a greater mean (±s.e.) reduction in weight of 5.9 ± 0.7% from randomization to week 24, as compared to 2.8 ± 0.7% for those assigned to BT + P”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size is a 3.1 percentage point difference in weight loss between groups, which is statistically significant but not anchored to a minimal clinically important difference or a clear biological/clinical meaningfulness threshold. The paper mentions that a ≥5% weight loss is clinically meaningful, but the between-group difference is below this threshold.
“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73, P = 0.003”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported double-blind RCT evaluating phentermine added to behavioral treatment in early nonresponders. The study design is rigorous with adequate randomization, blinding, power analysis, and pre-specified criteria. Minor reporting inconsistencies (e.g., Cohen's d discrepancy) and a few clarity issues are present but do not undermine the overall integrity.

Both reviewers classified the study as interventional (RCT), and this was adopted. The evaluation covered the full text, with all eight dimensions applicable. Not-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 3 tests; other reported statistics were not machine-verified and should not be assumed correct.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .003 · recomputed p = .002Reviewer 1
Primary outcome p-value from mean difference and CI
“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73, P = 0.003”
Find in source
Taken as given: The mean difference is 3.1 and the 95% CI is 1.1 to 5.1.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(3.1, 1.1, 5.1, 0)
CONSISTENTreported p = .012 · recomputed p = .009Reviewers 1, 2
Secondary outcome chi-square p-value for ≥5% weight loss
“53.9% of BT + AOM participants lost ≥5% of body weight compared to 25.3% of participants assigned to BT + P ( χ2(1) = 6.32, P = 0.012)”
Find in source
Taken as given: The percentages are based on the randomized groups of 38 each.; The counts are 20 (53.9% of 38) and 9 (25.3% of 38).; The chi-square test is two-sided with 1 degree of freedom.
Method: Recomputed Pearson chi-square p-value from the 2x2 table of counts.
How we recomputed it: pChi2x2(20, 18, 9, 29)
CONSISTENTreported p = .003 · recomputed p = .002Reviewer 2
Primary outcome: difference in percent weight loss between groups (from randomization) - p-value from mixed model.
“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73, P = 0.003”
Find in source
Taken as given: The estimate is the mean difference (3.1) and the 95% CI is (1.1, 5.1).; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed two-tailed p from estimate and 95% CI using normal approximation.
How we recomputed it: pCI(3.1, 1.1, 5.1, 0)

lowinternal contradiction
The text states that 76 early nonresponders were randomized, but the CONSORT diagram and Table 1 show 76, which is consistent. However, the text mentions '16 participants did not enroll in phase 2, leaving 131 who did' but earlier says 147 enrolled in phase 1, and 5 were removed due to COVID, leaving 142, and 11 more were excluded, leaving 131. This is consistent.
“Sixteen participants did not enroll in phase 2, leaving 131 who did.”
ResultsFind in source
lowinternal contradiction
The number of participants missing vitals is described as 14 nonresponders (18.4%) and later as 8 (10.5%) attributable to noncompletion, with 19 (25%) missing due to COVID-19; these numbers may overlap.
Vitals were missing for the 14 nonresponders (18.4%) who completed only remote measures... An additional three early nonresponders elected to complete the week-24 assessment remotely after our site reopened. Thus, a total of eight (10.5%) nonresponders had missing vitals and laboratory outcomes that were attributable to noncompletion...
Resultsreviewer’s wording
lowinternal contradiction
The abstract reports Cohen's d = 0.73 for the primary outcome, while Table 2 reports d = 0.72 for the same comparison.
Cohen’s d = 0.73 (Abstract) vs 0.72 (Table 2)
Table 2reviewer’s wording

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

partialReviewer 2
AOMs can be introduced early in treatment once lack of response to behavioral intervention has been observed rather than waiting ≥6 months to modify therapy.
The study shows benefit of early introduction, but long-term outcomes and comparison to later introduction are not tested, so the claim is partially supported.
Evidence: The trial introduced AOM at week 4 and showed benefit, but no comparison to delayed introduction.
“They also suggest that AOMs can be introduced early in treatment once lack of response to behavioral intervention has been observed rather than waiting ≥6 months to modify therapy.”
Discussion ¶1Find in source
supportedReviewers 1, 2
Stepping up early BT nonresponders to BT + AOM improves their 24-week weight loss.
The primary outcome showed a significantly greater weight loss in the AOM group, supporting the claim.
Evidence: Primary outcome: mean difference = 3.1%, 95% CI = 1.1–5.1%, P = 0.003.
“Stepping up early BT nonresponders to BT + AOM improves their 24-week weight loss.”
AbstractFind in source
supportedReviewers 1, 2
The addition of AOM more than doubled the mean weight loss at 24 weeks postrandomization.
The mean weight loss was 5.9% in AOM vs 2.8% in placebo, which is more than double.
Evidence: Primary outcome: 5.9% vs 2.8%.
the addition of the AOM, phentermine of 15.0 mg d−1, more than doubled the mean weight loss at 24 weeks postrandomization
Discussion ¶1reviewer’s wording
supportedReviewers 1, 2
Only 25.3% of early nonresponders achieved ≥5% weight loss with standard care, whereas over half (53.9%) achieved it with AOM.
These percentages are reported in the secondary outcomes and are consistent.
Evidence: Secondary outcome: 53.9% vs 25.3%, chi-square P = 0.012.
“Only 25.3% of early nonresponders achieved a weight loss of ≥5% from randomization to week 24 with the current standard of care of 6 months of intensive BT (with placebo), whereas over half (53.9%) achieved this target when AOM was added.”
Discussion ¶1Find in source
supportedReviewers 1, 2
The results strongly support clinical guidelines that recommend the addition of AOMs for patients who do not achieve clinically meaningful weight loss with BT alone.
The trial provides direct evidence for this recommendation.
Evidence: Primary and secondary outcomes show benefit of AOM.
“The present results strongly support clinical guidelines that recommend the addition of AOMs for patients who do not achieve clinically meaningful weight loss with BT alone”
Discussion ¶1Find in source
supportedReviewer 1
Phentermine-treated participants experienced larger-than-expected mean increases in systolic and diastolic BP.
The increase in systolic BP was significant, and diastolic BP increased, though not significantly.
Evidence: Systolic BP increased by 6.6 mm Hg (P=0.007), diastolic by 4.9 mm Hg (P=0.166).
“phentermine-treated participants experienced larger-than-expected mean increases from randomization in systolic and diastolic BP of 6.6 and 4.9 mm Hg, respectively.”
Discussion ¶5Find in source

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy claim is based on weight loss percentage, which is a surrogate endpoint for clinical outcomes such as cardiovascular morbidity and mortality. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking weight loss to hard clinical outcomes in this specific context.
“The primary outcome was met; early nonresponders assigned to BT + AOM had a greater mean (±s.e.) reduction in weight of 5.9 ± 0.7% from randomization to week 24, as compared to 2.8 ± 0.7% for those assigned to BT + P”
Find in source
INADEQUATEEffect size
The reported effect size is a 3.1 percentage point difference in weight loss between groups, which is statistically significant but not anchored to a minimal clinically important difference or a clear biological/clinical meaningfulness threshold. The paper mentions that a ≥5% weight loss is clinically meaningful, but the between-group difference is below this threshold.
“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73, P = 0.003”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple studies on behavioral treatment, early nonresponse, and anti-obesity medications, and clearly identifies the gap: no randomized trial has tested adding AOM to BT in early nonresponders. The rationale is well-articulated, and the study directly addresses this gap. Limitations of prior work are acknowledged, such as the lack of studies on rapid step-up approaches.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

“To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

Introduction ¶1Find in source

“Remarkably, the recommendation to offer AOM to individuals who are unable to successfully lose weight with BT alone has never been tested in a randomized trial.”

Introduction ¶4Find in source

“To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Several studies have examined the efficacy of stepped-care approaches for obesity treatment... To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

“Remarkably, the recommendation to offer AOM to individuals who are unable to successfully lose weight with BT alone has never been tested in a randomized trial.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 3]

“The baseline treatment offered in these programs has typically been of low intensity... and treatment has primarily been intensified by increasing provider contact rather than by offering an adjunctive intervention.”

The trial is described as double-blind, randomized, with permuted blocks and random number tables. Blinding is stated (double-blind). A priori power calculation is provided. Inclusion/exclusion criteria are detailed. The analysis population (ITT) and missing data handling (mixed models, multiple imputation) are described. The study is a single-center RCT, and independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study design is rigorous with clear randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization]

“early nonresponders—who lost <2.0% of baseline weight—were randomly assigned 1:1 to the AOM phentermine (15 mg d−1) or placebo in permuted blocks of 2–4 participants via random number tables.”

“was a single-center, double-blinded, parallel-group design randomized controlled trial”

MethodsFind in source

“a randomized sample of 50 nonresponders (25 per group) was expected to provide 81.5% power to detect between-group differences at week 24 in the primary outcome (two-tailed α level = 0.05).”

MethodsFind in source

PASSReviewer 2· 90% conf

The RCT design is rigorous with adequate randomization, blinding, power analysis, and pre-specified criteria.

Evidence

paraphrase[Methods, Randomization]

“was a single-center, double-blinded, parallel-group design randomized controlled trial”

MethodsFind in source

“a randomized sample of 50 nonresponders (25 per group) was expected to provide 81.5% power to detect between-group differences at week 24 in the primary outcome (two-tailed α level = 0.05).”

MethodsFind in source

The paper reports sex (predominantly female), age, weight, BMI, and race/ethnicity for the run-in cohort and the randomized groups. Since both sexes are enrolled, sex_justified is not applicable. Health status is partially reported via exclusion criteria and baseline characteristics. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, BMI, and race/ethnicity.

Evidence

paraphrase[Results, Phase 1]

“The 147 participants who passed the screening and enrolled in the 4-week BT run-in were predominantly female (87.1%, n = 128); 80 (54.5%) self-identified as white, 57 (38.8%) as Black and 5 (3.4%) as Asian; 7 (4.8%) identified as Hispanic. Participants had a mean baseline age of 48.5 years (s.d. = 12.4), weight of 104.6 kg (s.d. = 19.8) and BMI of 37.7 kg m−2 (s.d. = 6.4”

“Sex (female), n (%) | 66 (86.8%) | 30 (78.9%) | 36 (94.7%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported for this human trial.

Evidence

ResultsFind in source

paraphrase[Results, Phase 1]

“Participants had a mean baseline age of 48.5 years (s.d. = 12.4), weight of 104.6 kg (s.d. = 19.8) and BMI of 37.7 kg m−2 (s.d. = 6.4”

The study was approved by the University of Pennsylvania IRB, and written informed consent was obtained. Compliance with ethical standards is implied through IRB approval and trial registration.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval and informed consent are clearly documented.

Evidence

“conducted at the University of Pennsylvania, whose institutional review board approved the study protocol”

MethodsFind in source

“who obtained written informed consent and assessed applicants’ behavioral and psychological eligibility.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately documented.

Evidence

“conducted at the University of Pennsylvania, whose institutional review board approved the study protocol”

MethodsFind in source

“who obtained written informed consent and assessed applicants’ behavioral and psychological eligibility.”

MethodsFind in source

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

Phentermine is identified by name, dose, and manufacturer (not explicitly, but the drug is well-known). The study uses a digital scale (Tanita, BWB800) and home scales (EatSmart, ESBS-01). Statistical software (SPSS, R) is identified. No antibodies, cell lines, or other biological reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (phentermine) is adequately identified, and software tools are named.

Evidence

paraphrase[Abstract and Methods]

“BT plus AOM (phentermine = 15.0 mg d−1, n = 38)”

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (phentermine) and software are adequately identified.

Evidence

paraphrase[Methods, Phase 2]

“Phentermine was provided as 8.0 mg d−1 for the first 2 weeks to facilitate its acceptance. The dose was then increased at week 2–15 mg d−1”

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

The primary analysis uses mixed-effects models, which are appropriate for repeated measures. Tests are named (mixed-effects models, chi-square). Exact p-values are reported (e.g., P = 0.003). Effect sizes with confidence intervals are provided (e.g., mean difference = 3.1 ± 1.0, 95% CI = 1.1–5.1%). Software is identified. Data presentation includes individual data points in waterfall plots and error bars defined. Mathematical plausibility checks were not performed due to continuous outcomes and model-derived estimates.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

paraphrase[Abstract]

“P = 0.003”

“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%”

AbstractFind in source

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“Mean percentage reductions in initial weight in the intention-to-treat population were compared using mixed-effects models”

Statistical analysisFind in source

paraphrase[Abstract]

“P = 0.003”

“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73”

AbstractFind in source

The data availability statement provides a clear mechanism for accessing de-identified data through a review process and data-sharing agreement. It explains why data cannot be freely available due to privacy. Code availability states that no custom code was generated, and standard software was used. Repository deposit and accession numbers are not applicable for patient-level data.

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is concrete, and code availability is addressed.

Evidence

“Data will be provided following the review and approval of a research proposal (including a statistical analysis plan) by the corresponding author and at least one other doctoral-level researcher at the University of Pennsylvania.”

Data availabilityFind in source

“No custom code was generated for the present analyses.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly described with a managed-access procedure, and code is not applicable.

Evidence

“De-identified participant data used in the present analyses will be made available to investigators for research purposes after release of this publication. Data will be provided following the review and approval of a research proposal (including a statistical analysis plan) by the corresponding author and at least one other doctoral-level researcher at the University of Pennsylvania. The initial review will be completed within 3 months of receipt of the proposal.”

Data availabilityFind in source

“No custom code was generated for the present analyses.”

Data availabilityFind in source

The trial is registered (NCT03779048). A CONSORT 2010 checklist is mentioned in supplementary information. All outcomes are reported, including secondary and exploratory. Limitations are discussed in detail. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, CONSORT checklist, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

“Supplementary Note (CONSORT 2010 checklist, summary of protocol modifications and full study protocol).”

Supplementary materialFind in source

“The primary limitation of this study was the relatively small sample of randomized participants, which was not adequately powered to detect group differences in outcomes other than percent reduction in body weight.”

Discussion ¶7Find in source

PASSReviewer 2· 90% conf

Reporting is complete with trial registration, CONSORT checklist, limitations, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

“Supplementary Note (CONSORT 2010 checklist, summary of protocol modifications and full study protocol).”

Supplementary materialFind in source

Discussion ¶7Find in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

ClinicalTrials.gov

NCT03779048

Reporting guidelines: CONSORT

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 36 references by DOI: 2 verified — 34 no DOI (shown, not verified).

NO DOI
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Interpreting weight losses from lifestyle modification trials: using categorical data
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Evaluation of early weight loss thresholds for identifying nonresponders to an intensive lifestyle intervention
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Predictors of attrition and weight loss success: results from a randomized controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Early-treatment weight loss predicts 6-month weight loss in women with obesity and depression: implications for stepped care
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Is drop-out from obesity treatment a predictable and preventable event?
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A preliminary investigation into whether early intervention can improve weight loss among those initially non-responsive to an internet-based behavioral program
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Successful weight loss with self-help: a stepped-care approach
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of a stepped-care intervention approach on weight loss in adults: a randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Early weight loss in behavioral treatment predicts later rate of weight loss and response to pharmacotherapy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse‐controlled release for obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Safety and effectiveness of longer‐term phentermine use: clinical outcomes from an electronic health record cohort
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Comparison of continuous and intermittent anorectic therapy in obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The Diabetes Prevention Program (DPP) description of lifestyle intervention
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide once weekly for the treatment of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Once-weekly semaglutide in adults with overweight or obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical opportunities
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A protocol to deliver intensive behavioral therapy (IBT) for obesity in primary care settings: the MODEL‐IBT program
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Development of a brief measure to assess quality of life in obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The PHQ‐9: validity of a brief depression severity measure
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Physical activity as an index of heart attack risk in college alumni
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Pattern-mixture models for multivariate incomplete data
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
How many imputations are really needed? Some practical clarifications of multiple imputation theory
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Multiple imputation after 18+ years
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

2 of 3 data/code links checked; 2 live; 1 not probed.

datahttps://clinicaltrials.gov/study/NCT03779048LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/ct2/show/NCT03779048LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
codehttps://www.rproject.org/UNVERIFIED
Liveness indeterminate — content not checked.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

MINORconsistencyAbstract
“Cohen’s d = 0.73”
→ Ensure consistency with Table 2 where Cohen's d is reported as 0.72 for the primary outcome.
The abstract reports d=0.73 while Table 2 reports d=0.72 for the same comparison.
MINORclarityMethods, Statistical analyses
“In mixed-effects analyses with only two time points, individuals with missing data do not contribute to slope estimation, resulting in a completer analysis.”
→ Clarify that this applies to the primary outcome analysis and how missing data are handled in the mixed model.
The sentence is slightly confusing; it could be clearer that the mixed model uses available data.
MINORtypoResults, Phase 2
“Vitals were missing for the 14 nonresponders (18.4%) who completed only remote measures”
→ Change 'nonresponders' to 'participants' for clarity.
The term 'nonresponders' is used to refer to early nonresponders, but here it refers to all participants with missing vitals.
MINORconsistencyAbstract
“Cohen’s d = 0.73”
→ Ensure consistency with Table 2 where Cohen's d is reported as 0.72 for the same comparison.
Minor discrepancy in effect size between abstract and table.
MINORclarityResults, Phase 2
“Vitals were missing for the 14 nonresponders (18.4%) who completed only remote measures”
→ Clarify whether 'nonresponders' refers to early nonresponders or all participants.
Potential ambiguity in terminology.
MINORgrammarDiscussion, paragraph 3
“The results demonstrated that individuals at risk of suboptimal response, as defined by their loss of <2% of initial weight in the first 4 weeks, can achieve a weight loss similar to that of early (strong) BT responders if provided with adjunctive AOM at that time.”
→ Consider rephrasing for clarity: '...if they are provided with adjunctive AOM at that time.'
Minor grammatical improvement.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor inconsistencies (Cohen's d discrepancy, terminology ambiguity) and the small sample size as limitations, but these do not warrant a correction. The data availability statement is adequate, and no integrity concerns were raised.

1.
HIGHcopyedit
Reconcile the Cohen's d value for the primary outcome between the Abstract (0.73) and Table 2 (0.72) to ensure consistency.
An internal inconsistency in a reported effect size could confuse readers and undermine trust in the reported results.
2.
HIGHcopyedit
Clarify the term 'nonresponders' in the Results section (Phase 2) where it refers to participants with missing vitals, to avoid ambiguity with early nonresponders.
Ambiguous terminology could mislead readers about which participant subgroup is being described.
3.
MEDIUMreporting
Clarify the sentence in Methods, Statistical analyses about missing data in mixed-effects models to explicitly state how missing data are handled for the primary outcome.
The current wording is confusing and could be misinterpreted regarding the analysis population.
4.
MEDIUMreporting
Consider reporting the exact p-value for the secondary outcome of ≥10% weight loss (currently reported as P = 0.078) to enhance precision.
Exact p-values are preferred over threshold reporting for transparency and reproducibility.
5.
MEDIUMreporting
Consider reporting the exact p-value for the exploratory comparison between early responders and BT+AOM (currently reported as not significant without a value).
Providing exact p-values for all reported comparisons improves completeness.
6.
MEDIUMdata code
Consider specifying the exact data-sharing agreement terms or providing a link to the protocol repository in the Data Availability statement.
More specific access details would facilitate data reuse and enhance transparency.
7.
MEDIUMreporting
Consider adding a statement about the handling of missing data for the primary outcome in the CONSORT flow diagram to improve transparency.
Clear reporting of missing data handling is essential for assessing potential bias.
8.
MEDIUMreporting
Consider reporting the intraclass correlation or variance components from the mixed models to aid replication.
Providing model parameters would allow others to replicate the analysis more accurately.
9.
MEDIUMreporting
Consider providing the full statistical analysis plan as a supplementary file to strengthen reproducibility.
A full SAP would enhance transparency and allow verification of pre-specified analyses.
10.
MEDIUMreporting
Consider reporting the number of participants who discontinued treatment and the reasons in a more detailed table.
Detailed discontinuation information is important for assessing attrition bias.
11.
MEDIUMrigor
Consider adding a sensitivity analysis excluding participants with remote weight measurements to assess robustness.
Remote measurements may introduce measurement variability; a sensitivity analysis would strengthen the conclusions.
12.
LOWreporting
Consider reporting the manufacturer and lot number for phentermine and placebo in the Methods to fully satisfy resource identification.
Providing product details enhances reproducibility and resource identification.
13.
LOWreporting
Consider providing a more detailed description of the randomization sequence generation and allocation concealment in the Methods.
More detail on randomization procedures would further strengthen the design description.
14.
LOWethics
Consider adding a statement about adherence to the Declaration of Helsinki or other ethical guidelines in the Methods.
Explicitly stating adherence to ethical guidelines is a good practice for human research.
15.
LOWcopyedit
Rephrase the sentence in Discussion, paragraph 3 for grammatical clarity: '...if they are provided with adjunctive AOM at that time.'
Minor grammatical improvement enhances readability.

Full text (65,150 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA

DOI

10.1038/s41591-025-03556-3

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20